Final Analysis of the Randomized Phase 2 Part of the ASPEN-06 Study: A Phase 2/3 Study of Evorpacept (ALX148), a CD47 Myeloid Checkpoint Inhibitor, in Patients with HER2-overexpressing Gastric/gastroesophageal Cancer (GC).
Journal of Clinical Oncology(2025)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined